LGR4/5 receptors and their cognate RSPO ligands potentiate Wnt/β-catenin signalling and promote proliferation and tissue homeostasis in epithelial stem cell compartments. In the liver, metabolic zonation requires a Wnt/β-catenin signalling gradient, but the instructive mechanism controlling its spatiotemporal regulation is not known. We have now identified the RSPO-LGR4/5-ZNRF3/RNF43 module as a master regulator of Wnt/β-catenin-mediated metabolic liver zonation. Liver-specific LGR4/5 loss of function (LOF) or RSPO blockade disrupted hepatic Wnt/β-catenin signalling and zonation. Conversely, pathway activation in ZNRF3/RNF43 LOF mice or with recombinant RSPO1 protein expanded the hepatic Wnt/β-catenin signalling gradient in a reversible and LGR4/5-dependent manner. Recombinant RSPO1 protein increased liver size and improved liver regeneration, whereas LGR4/5 LOF caused the opposite effects, resulting in hypoplastic livers. Furthermore, we show that LGR4 + hepatocytes throughout the lobule contribute to liver homeostasis without zonal dominance. Taken together, our results indicate that the RSPO-LGR4/5-ZNRF3/RNF43 module controls metabolic liver zonation and is a hepatic growth/size rheostat during development, homeostasis and regeneration.
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LGR4/5 receptors and their cognate RSPO ligands potentiate Wnt/β-catenin signalling and promote proliferation and tissue homeostasis in epithelial stem cell compartments. In the liver, metabolic zonation requires a Wnt/β-catenin signalling gradient, but the instructive mechanism controlling its spatiotemporal regulation is not known. We have now identified the RSPO-LGR4/5-ZNRF3/RNF43 module as a master regulator of Wnt/β-catenin-mediated metabolic liver zonation. Liver-specific LGR4/5 loss of function (LOF) or RSPO blockade disrupted hepatic Wnt/β-catenin signalling and zonation. Conversely, pathway activation in ZNRF3/RNF43 LOF mice or with recombinant RSPO1 protein expanded the hepatic Wnt/β-catenin signalling gradient in a reversible and LGR4/5-dependent manner. Recombinant RSPO1 protein increased liver size and improved liver regeneration, whereas LGR4/5 LOF caused the opposite effects, resulting in hypoplastic livers. Furthermore, we show that LGR4 + hepatocytes throughout the lobule contribute to liver homeostasis without zonal dominance. Taken together, our results indicate that the RSPO-LGR4/5-ZNRF3/RNF43 module controls metabolic liver zonation and is a hepatic growth/size rheostat during development, homeostasis and regeneration.
Hepatic zonation and organ size control are required for physiological liver function, including metabolization of a wide range of endogenous products and xenobiotics. Hepatocyte function is determined by its position along the porto-central axis of the liver lobule, which creates a metabolic zonation. Complementary metabolic pathways occur within non-overlapping liver zones, thus maintaining optimal metabolic homeostasis [1] [2] [3] [4] [5] . Physiological liver size is tightly controlled by the concerted growth of hepatocytes and other hepatic cells during development, homeostasis and regeneration [6] [7] [8] . Recent studies have highlighted the Wnt/β-catenin pathway as a major regulator of liver zonation, development and regeneration 4, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Wnt pathway activation induces β-catenin target gene expression (for example, Axin2 and leukocyte cell-derived chemotaxin 2 (Lect2)) and expression of other Wnt/β-catenin-dependent genes (for example, glutamine synthetase (GS; GluL) and Cyp2e1) 19 . β-catenin deletion impaired metabolic liver zonation and hepatocyte proliferation, whereas pathway activation in adenomatous polyposis coli (APC) knockout (KO) or β-catenin overexpression in mice expanded Wnt/β-catenin signalling and caused uncontrolled growth 4, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . However, the instructive molecular cues for spatiotemporal control of Wnt/β-catenin signalling in liver zonation, development and regeneration have remained elusive.
R-spondin (RSPO)1-4 ligands potentiate Wnt/β-catenin signalling through leucine-rich repeat-containing G protein-coupled receptors 4-6 (LGR4-6) [20] [21] [22] [23] . RSPO binding to LGR4-6 receptors leads to increased Wnt signalling by clearing the cell-surface transmembrane E3 ubiquitin ligases, zinc and ring finger 3 (ZNRF3) and its homologue ring finger 43 (RNF43), which promote Wnt receptor turnover, from the plasma membrane 24, 25 . RSPO-LGR4/5-ZNRF3/RNF43 signalling plays an essential role in developing and maintaining various epithelial tissue stem cell compartments 21, 23, 26, 27 . The liver has a remarkable 1 plasticity with an intrinsically high capacity for context-dependent regeneration [28] [29] [30] [31] [32] .
LGR5 has been reported to be exclusively expressed around the portal vein only following injury 33, 34 , whereas undamaged livers have persistent high Wnt/β-catenin activity around the central vein 1, 35 . This is in contrast to other tissues where cells with high Wnt/β-catenin activity express LGR4 and LGR5 21, 23, 26, 27 . A potential role for RSPO-LGR4/5-ZNRF3/RNF43 signalling in the regulation of hepatic Wnt/β-catenin activity during liver development, homeostasis and regrowth has remained unclear.
Through integrated in vivo approaches comprising lineage tracing, pathway modulation and detailed expression analyses, we now show that the RSPO-LGR4/5-ZNRF3/RNF43 module controls metabolic liver zonation and acts as a hepatic growth/size rheostat during development, homeostasis and regeneration.
LGR4 and LGR5 are co-expressed in pericentral hepatocytes with high Wnt activity
To gain a detailed resolution of the hepatic Wnt/β-catenin signalling gradient regulating metabolic liver zonation, we assessed Wnt/β-catenin activity in different hepatic zones. Expression of GS, a Wnt/β-catenin-dependent protein and key enzyme in the ammonia detoxification pathway 17 ( Fig. 1a,c) , and β-catenin reporter activity in Tcf/Lef-Venus mice 36 ( Fig. 1b,c) , were restricted to the first layers of hepatocytes around the central vein. Similarly, in situ hybridization (ISH) showed that Axin2 messenger RNA (mRNA) was predominantly expressed in these cells (Fig. 1d,e) . Expression of CYP2E1, another metabolic enzyme and Wnt/β-catenin-dependent protein 37 , extended into the parenchyma adjacent to the central veins (Fig. 1a,c) . This suggests differential expression of Wnt/β-catenin-dependent genes along the centro-portal Wnt/β-catenin signalling gradient, possibly because of different inductive thresholds or transcriptional regulation for these genes. To explore whether LGR4, LGR5, ZNRF3 and RNF43 contribute to the Wnt/β-catenin signalling gradient and liver zonation, we performed a detailed expression analysis. Using ISH, we found Lgr5 expression mainly restricted to pericentral hepatocytes with high Wnt activity. Almost all hepatocytes adjacent to the central vein expressed Lgr5, whereas it was expressed only in a negligible minority of parenchymal hepatocytes. Lgr4, which was co-expressed with Lgr5 in pericentral hepatocytes, was expressed in virtually all hepatocytes across the liver lobule (Fig. 1f,g and Supplementary  Fig. 1a,b) . Znrf3 was broadly expressed in hepatocytes throughout the liver (Fig. 1h,i) , whereas LacZ expression in Rnf43-LacZ mice ( Supplementary Fig. 1c ) was restricted to central vein hepatocytes (Fig. 1j,k) . To further explore the roles of LGR4 and LGR5 in the liver, we performed lineage tracing experiments using mice expressing tamoxifen (TAM)-inducible Cre (CreERT2) from the Lgr4 (Lgr4ki mice) or Lgr5 (Lgr5ki mice) loci 26 , crossed with Rosa26 (R26)-β-galactosidase (β-Gal; LacZ) 38 , R26-tdTomato (tdTOM) or R26-enhanced green fluorescent protein (EGFP) reporter mice ( Supplementary Fig. 2a ). Ten-day lineage tracing in Lgr4ki/R26-LacZ mice labelled hepatocytes throughout the liver, confirming broad LGR4 expression ( Fig. 2a and Supplementary Fig. 2b ). Ten-month LGR4 lineage tracing showed a similar expression pattern with small LacZ + hepatocyte clones consisting of 1-5 cells, in line with low rates of homeostatic cell division 5 (Fig. 2b,c and Supplementary  Fig. 2b ). Similarly sized clones of LGR4-lineage-traced pericentral, parenchymal and periportal hepatocytes suggest similar proliferation rates within the three different liver zones (Fig. 2c) . Ten-day lineage tracing in Lgr5ki/R26-LacZ mice confirmed that LGR5 expression is restricted to pericentral hepatocytes ( Fig. 2d and Supplementary  Fig. 2c ). Eighteen-month lineage tracing and distribution analysis across different zones indicated that LGR5
+ hepatocytes remained at the central vein as small clones consisting of 1-5 cells (Fig. 2e,f and Supplementary Fig. 2c,d ). Co-expression of Axin2 and Lgr5 mRNA in virtually all of the LGR5-lineage-traced hepatocytes confirmed active Wnt signalling in these cells ( Supplementary Fig. 2e-g ). Moreover, Ki67 staining in the LGR5-lineage-traced hepatocytes 48 h post-partial hepatectomy (PH) indicated that the proliferation capacity of these cells was similar compared to untraced neighbouring pericentral hepatocytes ( Supplementary Fig. 2h-j) . A comparative 7-day EdU proliferation analysis in Lgr5ki and wild-type (WT) mice showed that the absence of one of the Lgr5 alleles did not impair homeostatic proliferation of pericentral hepatocytes (Fig. 2i,j) . Tenday lineage tracing in Lgr4ki/R26-EGFP (Fig. 2g ) and Lgr5ki/R26-tdTOM mice (Fig. 2h ) and co-staining of labelled cells with the hepatocyte markers hepatocyte nuclear factor 4 alpha (HNF4α) or GS, respectively, confirmed that the traced cells were indeed hepatocytes. In gut and skin, LGR4 is more broadly expressed than the Wnt target LGR5, which is restricted to tissue stem cells with high Wnt activity [39] [40] [41] . Similarly, we observed a broad expression of LGR4 in hepatocytes throughout the liver, whereas LGR5 expression was restricted to pericentral hepatocytes with high Wnt activity. Despite persistent high Wnt activity and LGR5 expression, pericentral hepatocytes rarely proliferated and did not exhibit increased proliferation rates when compared to those of other hepatic zones, as indicated both by EdU labelling (Fig. 2i ,k-m and Supplementary Fig. 2k -n) and Ki67 immunostaining (Fig. 2n-p) . This is in contrast to actively cycling LGR5 + cells in tissue stem cell compartments of other organs 27 . In undamaged livers, most (>80%) proliferating cells were found in the liver parenchyma (Fig. 2m,p and Supplementary Fig. 2n ), itself the largest hepatic zone, indicating that parenchymal hepatocytes account for most new hepatocytes during liver homeostasis. Our findings are consistent with previous reports showing that most proliferating hepatocytes reside in the parenchyma and that hepatocytes throughout the lobule contribute to liver homeostasis without zonal dominance 42, 43 .
LGR4 and LGR5 receptors are essential for metabolic liver zonation
To delineate whether LGR4 and LGR5 are mediating the instructive cues that establish the hepatic Wnt/β-catenin signalling gradient and liver zonation, we generated liver-specific Lgr4 KO (Lgr4LKO), Lgr5 KO (Lgr5LKO) and Lgr4/5 double-KO (Lgr4/5dLKO) mice using albumin (Alb)Cre-mediated deletion ( Supplementary Fig. 1d ). Lgr4LKO and Lgr4/5dLKO, but not Lgr5LKO mice showed reduced liver weight when compared with control mice (Fig. 3a) . Loss of Lgr4 and Lgr5 mRNA in the liver was confirmed by polymerase chain reaction with reverse transcription (RT-PCR) (Fig. 3b) and ISH (Fig. 3c) . Whereas no overt changes were observed in Lgr5LKO mice, Wnt/β-catenin signalling was abrogated in Lgr4/5dLKO and Lgr4LKO mice, as indicated by loss of Axin2 and Lect2 expression. Lgr5 mRNA expression was absent following Lgr4 deletion (Fig. 3b,c) , similar to findings in the developing intestinal epithelium 26 . This suggests a dominant role for LGR4 over LGR5, and that loss of Lgr5 expression is a result of abrogated Wnt signalling. GS staining was severely reduced in Lgr4LKO and completely lost in Lgr4/5dLKO mice compared with control mice (Fig. 3d,e) . Likewise, Lgr4 and Lgr4/5 deletion impaired CYP2E1 expression (Fig. 3f,g ). Early postnatal analysis of Lgr4/5dLKO mice showed reduced GS expression already at postnatal day (P)2 that remained low on P10 and P30, whereas it was A R T I C L E S LGR4 (10 months)
LGR5 (18 months) Figure 2 LGR4 and LGR5 lineage tracing during liver homeostasis. RT-PCR (b,i,j) was run in triplicates and experiments were repeated 3 times. Data represent mean ± s.d. * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001; * * * * * P < 0.00001; NS, not significant; twotailed unpaired t-test (i,j) and one-way ANOVA with Tukey's test (a,b,e,g) were used. Scale bars, 20 µm (c), 200 µm (d,f) and 20 µm (magnifications in d,f).
increased in control mice from P2 to P10 ( Supplementary Fig. 3a,b) . P2, P10 and P30 Lgr4/5dLKO mice showed functional hepatocyte and biliary cell differentiation, as evidenced by normal distribution of HNF4α + hepatocytes, SRY (sex determining region Y)-box 9 (SOX9) + /cytokeratin 19 (CK19) + biliary ducts and absence of SOX9 in hepatocytes ( Supplementary Fig. 3c,d ), excluding the possibility that compromised hepatocyte differentiation during liver development accounts for the impaired metabolic zonation. To study the mechanistic consequences of liver-specific Lgr4/5 deletion, we performed high-throughput RNA sequencing (RNA-Seq) on total liver RNA samples isolated from control and Lgr4/5dLKO mice. Expression of Wnt target genes (for example, Axin2, Lect2 and tumour necrosis factor receptor superfamily, member 19 (Tnfrsf19) as well as gene sets for Wnt signalling and metabolic processes were significantly downregulated ( Supplementary Fig. 4a ,b and Supplementary Tables 1 and 2 ). Pericentrally expressed metabolic genes 44 were downregulated, whereas few periportal genes (Hsd17b13 and Hal) were significantly upregulated ( Fig. 3h and Supplementary  Fig. 4a ). RT-PCR analysis confirmed downregulation of pericentral metabolic genes (Glul, Cyp2e1 and Cyp1a2) and upregulation of Hsd17b13 and Hal (Fig. 3i,j) . This indicates that loss of hepatic Wnt/β-catenin signalling in Lgr4/5dLKO mice results in loss of metabolic liver zonation. RT-PCR and immunostaining confirmed that periportal metabolic genes, which were upregulated in β-catenin KO mice or mice with virus-mediated DKK1 overexpression 10, 12 , were not upregulated in Lgr4/5dLKO compared to control mice ( Fig. 3j and Supplementary Fig. 4c,d ). It is possible that inactivation or deletion of Wnt pathway components at different hierarchical levels results in distinct signalling output events that might account for these differences; for example, Lgr4/5 deletion was also shown to impair non-canonical Wnt signalling, in contrast to β-catenin deletion or DKK1 overexpression 22, 45 . Taken together, we identified an essential role for LGR4 and LGR5 receptors in spatial regulation of the centroportal Wnt/β-catenin signalling gradient and metabolic liver zonation.
A R T I C L E S

RSPO controls liver zonation through LGR4 and LGR5 receptors
Overexpression of the extracellular domain of ZNRF3 (ZNRF3ECD) was shown to block endogenous RSPO function by blocking RSPO1-induced membrane accumulation of Frizzled proteins 24 . To analyse whether RSPO proteins control the hepatic Wnt/β-catenin signalling gradient, we generated BAC-transgenic mice that allow doxycycline (DOX)-induced ubiquitous expression of the ZNRF3ECD (Znrf3ECD mice) and crossed these mice with Axin2-LacZ mice to obtain double transgenic Znrf3ECD/Axin2-LacZ mice (Fig. 4a) . diet, indicating that loss of endogenous RSPO function impaired the hepatic Wnt/β-catenin activity gradient (Fig. 4b,c) . Likewise, GS (Fig. 4d,e) and CYP2E1 (Fig. 4f,g ) expression was markedly reduced in Znrf3ECD/Axin2-LacZ mice fed with a DOX-containing diet. We next generated mice that allowed for the inducible combined deletion of Znrf3 and Rnf43 using TAM (Znrf3/Rnf43dfl;R26CreERT2 mice; Fig. 5a ). TAM injections resulted in a marked increase in GS (Fig. 5b,c) and CYP2E1 (Fig. 5d,e) expression in Znrf3/Rnf43dfl;R26CreERT2 mice when compared with Znrf3/Rnf43dfl;R26CreERT2 mice without TAM, with CYP2E1 expression even expanding into portal vein hepatocytes (Fig. 5d) . Thus, the LGR4/5-ZNRF3/RNF43 complex is a key regulator of the hepatic Wnt/β-catenin signalling gradient and metabolic liver zonation.
To further study the effect of RSPO in liver zonation, we administered recombinant RSPO1 (10 mg kg −1 ) or PBS twice weekly to Lgr4/5dLKO and control mice for 1 week, 2 weeks and 2 weeks followed by 4 weeks off-treatment (wash-out) (Fig. 6a) . The 2 weeks RSPO1 injection in adult WT mice and 2 weeks RSPO1 injection in Tcf/Lef-Venus mice markedly increased Axin2 mRNA (Fig. 6b,c) and Wnt/β-catenin reporter expression (Fig. 6d,e) , respectively. Importantly, RSPO1 injections expanded Wnt/β-catenin signalling into periportal hepatocytes, indicating that all cells across the liver lobule are competent to respond to Wnt pathway activation. Likewise, RSPO injections increased GS (Fig. 6f,g ) and CYP2E1 (Fig. 6h,i ) expression in control mice but not in Lgr4/5dLKO mice after 1 week. After 2 weeks, additional RSPO1 injections further expanded GS and CYP2E1 expression, which were reduced to PBS control levels after an additional 4 weeks off-treatment (Fig. 6f-i) . This further indicates that RSPO1 controls hepatic Wnt/β-catenin signalling in an LGR4/5-dependent manner to confer spatiotemporal regulation of the centro-portal Wnt/β-catenin activity gradient and metabolic liver zonation. It also indicates that sustained signalling through the RSPO-LGR4/5-ZNRF3/RNF43 module is essential to maintain this zonation. Notably, RSPO1 injections or Znrf3/Rnf43 deletions did not result in immediate ectopic GS expression throughout the liver but caused progressing expansion along the centro-portal axis, similarly to what was observed in Apc mutant mice 10 . This suggests the possibility that other mechanisms contribute to regulating zonated GS expression; for example, YAP activity in periportal hepatocytes may restrict GS expression, as it was recently shown that YAP is expressed in a portocentral gradient and can negatively regulate GS 46, 47 . In summary, our data suggest that Wnt receptors and ligands are distributed throughout the liver lobule and that the RSPO-LGR4/5-ZNRF3/RNF43 module is essential for hepatic Wnt signalling and metabolic liver zonation.
Lgr4 and Lgr5 deletions impair postnatal liver development
Reduced liver weight and downregulation of gene sets involved in cell cycle regulation (Supplementary Fig. 4b ) indicated impaired growth control in Lgr4/5dLKO mice. Analysis of early postnatal development revealed impaired hepatocyte proliferation in Lgr4/5dLKO mice at P2 and P10, whereas no significant difference was observed at P30 with overall reduced proliferation rates ( Supplementary Fig. 5a-c) , and quantification for the indicated times for GS (f,g) and CYP2E1 (h,i) in control and Lgr4/5dLKO mice +/− RSPO1. Panels f and h were generated by automatic image stitching. n = 4 mice in i (control 2 weeks RSPO, and control 2 weeks RSPO + wash-out) and 5 mice (all other conditions). The images in b are representative for 10 mice, in d for 9 mice, in f for 40 mice, and in h for 38 mice, and the stainings were repeated 2 times. Data represent mean ± s.d. * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001; NS, not significant; two-way ANOVA with Sidak's test was used. when compared to control littermates. Notably, impaired proliferation was most evident in pericentral hepatocytes with high Wnt activity. Consequently, liver weight was significantly reduced in P10 and P30
and Lgr4/5 26 as well as WT littermates ( Supplementary Fig. 5e ,f) indicates that LGR4/5 are dispensable for embryonic liver growth at E16.5. Together, this suggests that reduced liver weight in Lgr4/5dLKO mice is a consequence of impaired hepatocyte proliferation during postnatal liver development.
RSPO controls liver size and regeneration through LGR4/5 receptors
To further investigate the role of RSPO-LGR4/5 signalling in hepatic growth/size control, we subjected Lgr4LKO, Lgr5LKO, Lgr4/5dLKO and control mice to PH (Fig. 7a) . At 2 days (d2) post-PH, liver weight was significantly reduced in Lgr4LKO and Lgr4/5dLKO but not in Lgr5LKO mice when compared to controls (Fig. 7b) . Ki67 immunostaining revealed that Lgr4LKO, Lgr5LKO and Lgr4/5dLKO mice showed impaired proliferation in pericentral hepatocytes (Fig. 7c) . In contrast, proliferation of parenchymal (Fig. 7d) and periportal (Fig. 7e) hepatocytes was impaired only in Lgr4LKO and Lgr4/5dLKO but not in Lgr5LKO mice when compared to control mice. Zonal differences in proliferation indicate that LGR receptors are required for proliferation in their respective expression zones. Interestingly, during the peak regenerative response post-PH in control mice, hepatocyte proliferation rates were generally lower around the central vein when compared with the portal vein and parenchyma (Fig. 7c-e) . RT-PCR for Axin2 showed activation of the Wnt/β-catenin pathway during liver regeneration (d2 post-PH) in control mice and confirmed lack of Axin2 expression in Lgr4/5dLKO mice (Fig. 7f) . Moreover, Axin2 ISH showed a global increase in Wnt/β-catenin signalling that extended to periportal hepatocytes at d2 post-PH ( Supplementary Fig. 6a,b) , similar to what was seen in mice with RSPO1 injections.
The above findings indicate that LGR4/5 LOF impaired hepatocyte proliferation during liver regeneration as a consequence of abrogated Wnt signalling. It was recently shown that liver progenitor markers, including LGR5, were upregulated d2 post-PH in periportal hepatocytes 34 . Although RNA-Seq analysis confirmed upregulation of progenitor markers (Krt7, Tnfsrf12a) in control mice d2 post-PH when compared with naive controls, Lgr5 expression was not increased (Supplementary Fig. 6c ). ISH analysis confirmed that neither Lgr5 nor Lgr4 was upregulated in periportal hepatocytes of control mice at d2 post-PH ( Supplementary Fig. 6d-f) . RNA-Seq of Lgr4/5dLKO compared to control livers at d2 post-PH further showed no change in liver progenitor marker expression (Sox9, Afp, Tnfsrf12a, Krt7, Krt19; Supplementary Fig. 6g ), suggesting that these cells did not contribute to impaired regeneration in Lgr4/5dLKO mice. RNA-Seq analysis further revealed that expression levels of Wnt target genes and gene sets implicated in cell cycle regulation and metabolism were downregulated in livers of regenerating Lgr4/5dLKO mice (Fig. 7g,h ). However, both at d4 and d7, hepatocyte proliferation was significantly increased in Lgr4/5dLKO when compared with control mice (Fig. 7i,j) , similar to the delayed onset of proliferation seen in β-catenin KO mice 9 . Despite increased proliferation at later phases of liver regeneration, Lgr4/5dLKO mice showed significant impairment in the magnitude and effectiveness of the regenerative response, resulting in a smaller final liver to body weight ratio compared with control mice (Fig. 7k) . This indicates that LGR4/5 are essential for the Wnt/β-cateninmediated early regenerative response that is required for establishing a normal liver to body weight ratio during regeneration. Lineage tracing in Lgr5ki/R26-LacZ mice following PH indicated that pericentral LGR5 + hepatocytes did not extensively populate the liver during regrowth ( Supplementary Fig. 6h,i) . Together, these findings highlight an important role for LGR4 and LGR5 in hepatocyte proliferation and liver size control during regeneration, with a dominant role for LGR4.
To study the role of RSPO in hepatic size control, we administered recombinant RSPO1 (10 mg kg −1 ) or PBS twice weekly to Lgr4/5dLKO and control mice for 1 week, 2 weeks and 2 weeks followed by 4 weeks off-treatment (see scheme in Fig. 6a) . The 1 week RSPO1 treatment in control mice significantly increased hepatocyte proliferation in all three liver zones when compared with PBS-injected control mice. The strongest increase in RSPO-induced proliferation around the portal vein was not paralleled by highest Wnt/β-catenin activity in the region, indicating that other pathways might contribute to this phenotype. Consequently, RSPO1 treatment in control mice resulted in increased liver weight when compared with PBS-injected mice, further increasing with prolonged treatment and decreasing on RSPO1 withdrawal. In Lgr4/5dLKO mice, RSPO1 treatment did not promote hepatocyte proliferation and liver weight gain (Fig. 8a-c) . Together, these findings indicate that RSPO1 increases liver size in a reversible and Lgr4/5-dependent manner. Likewise, Znrf3/Rnf43 deletion in Znrf3/Rnf43dfl;R26CreERT2 mice resulted in a marked increase in hepatocyte proliferation throughout the liver 7 days post-TAM injections when compared with Znrf3/Rnf43dfl;R26CreERT2 mice without TAM (Fig. 8d,e) , further suggesting availability of Wnt receptors and ligands throughout the liver.
Finally, we assessed the potential of recombinant RSPO1 for improving liver regeneration. We therefore injected control mice with 10 mg kg −1 RSPO1 on 2 consecutive days, subjected the mice to PH and monitored liver regrowth by magnetic resonance imaging (MRI; Fig. 8f ). Although liver weight was not changed during the early phase (d2) of regeneration in either PBS-or RSPO1-injected mice, the latter showed a significant increase in liver weight at d7 post-PH (Fig. 8g) . Consistently, an MRI time course showed increased liver size in RSPO1-injected mice during late phase regeneration (d6, d7) beyond levels of PBS-injected mice, whereas it was not changed before PH or at early stages of liver regeneration (Fig. 8h,i) . This indicates that increased RSPO1 levels overrule liver size control during regeneration. Most importantly, RSPO1 treatment accelerated liver regeneration because RSPO1-treated mice reached the final liver volume of control mice more rapidly. Taken together, RSPO-LGR4/5-ZNRF3/RNRF43 signalling acts as a hepatic growth/size rheostat during development, homeostasis and regeneration.
DISCUSSION
Our data support that the RSPO-LGR4/5-ZNRF3/RNF43 module controls spatiotemporal regulation of the hepatic Wnt/β-catenin activity gradient and metabolic liver zonation. A recent study suggested that Wnt9b confers Wnt/β-catenin activity restricted to the central vein 31 . We have now found that RSPO1 injections or Znrf3/Rnf43 deletions expanded Wnt/β-catenin activity to periportal hepatocytes, indicating that Wnt receptors and ligands are available throughout the liver. Complete loss of hepatic Wnt/β-catenin signalling following Lgr4/5 deletion indicates that the RSPO-LGR4/5-ZNRF3/RNF43 module is not just potentiating Wnt activity but is essential for functional Wnt/β-catenin signalling in the liver. Although (k) Relative liver weight of the indicated mice at d4 and d7 post-PH. n = 3 male mice (control d7 post-PH), 4 male mice (control d4 post-PH and Lgr4/5dLKO d7 post-PH) and 5 male mice (Lgr4/5dLKO d4 post-PH). The images in c-e and i are representative for 20 and 15 mice, respectively. Data represent mean ± s.d. * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001; NS, not significant; two-tailed unpaired t-test (b-e, j,k), one-way ANOVA with Tukey's test (f), empirical Bayes with Benjamini-Hochberg test (g), and weighted Kolmogorov-Smirnov (y axis) and Mann-Whitney U-test (x axis) with Benjamini-Hochberg test (h) were used. Scale bars, 100 µm.
our data suggest that RSPO proteins confer local restriction of hepatic Wnt activity, their source and distribution remain to be identified. A recent report that was published during the final revision of our manuscript suggests a role for pericentrally confined RSPO3 in metabolic liver zonation 48 .
In a variety of tissue stem cell compartments, LGR4
+ and LGR5 + cells are actively cycling and give rise to more mature cells with a high turnover [39] [40] [41] . Unlike other LGR5 + epithelial cells, pericentral LGR5
+ hepatocytes neither showed overt proliferation nor gave rise to hepatocytes distant to the central vein, either under homeostasis conditions or during regeneration post-PH. Moreover, EdU and Ki67 analyses in wild-type mice could not detect increased proliferation of pericentral hepatocytes when compared to those of other liver zones. Our findings did not support the results of a recent study that proposed that pericentral hepatocytes comprise liver stem cells repopulating large parts of the liver during homeostasis 31 . Another recent study suggested that periportal hepatocytes with low SOX9 expression levels are liver stem cells with high regenerative capacity during homeostasis and drug-induced liver damage caused by zonal injury at the central vein 29 . It has been speculated that the site of injury determines the site of regeneration and that hepatocytes in different hepatic zones may mutually support liver regeneration in opposing (f) Scheme depicting control mice that were injected intravenously with RSPO1 or PBS on 2 consecutive days and subjected to PH. (g) Relative liver weight of the indicated mice. n = 3 mice (d2) and 6 mice (d7). (h) Representative MRI liver sections of the indicated mice. (i) Liver volume growth curve of the indicated mice following RSPO1 or PBS injection and PH. n = 6 male mice per group. The images in a are representative for 60 mice, in d for 30 mice, and in h for 12 mice. Data represent mean ± s.d.
* P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001; NS, not significant; twotailed unpaired t-test (e,g), two-way ANOVA with Tukey's test (b,c), and twoway ANOVA with Sidak's test (i) were used. Scale bars, 50 µm (a,d) and 6 mm (h).
sides 28 . Studying homeostatic hepatocyte renewal or regenerative response to PH, a paradigm model for liver regeneration that is not biased by zonal injury, we now show that LGR4 + hepatocytes throughout the liver contribute to liver homeostasis and regeneration. Although most (>80%) proliferating hepatocytes during homeostasis were found in the parenchyma, proliferation rates between the three zones were similar. During the peak regenerative response postreduced proliferation of pericentral hepatocytes following PH 42, 49 . This indicates that parenchymal hepatocytes can have similar regenerative capacity to pericentral or periportal hepatocytes. Our data add to the emerging concept that there might not be just one liver stem cell compartment but that cells in different liver zones show increased regenerative potential depending on the injury 28, 32 . Despite recent advances in identifying cellular compartments that contribute to liver regeneration and maintenance [28] [29] [30] 32, 34, 43 , the detailed mechanisms that confer spatiotemporal control of proliferation to maintain proper liver size have remained elusive. We now show that increased RSPO-LGR4/5-ZNRF3/RNF43 signalling overrules the stop signals during liver regrowth or homeostasis, whereas Lgr4/5 deletions result in hypoplastic livers. Likewise, Lgr4/5 deletions impair liver regeneration, whereas RSPO1 injections accelerate regeneration. This suggests that the RSPO-LGR4/5-ZNRF3/RNF43 module acts as rheostat controlling liver growth and size. Our data further highlight important roles of ZNRF3 and RNF43 in restricting proliferation in the liver, consistent with Rnf43 mutations observed in liver tumours 50 .
Recently, periportal LGR5
+ progenitor cells were identified following drug/diet-induced liver damage 33 . In contrast to our study, no LGR5
+ cells were found in livers of naive mice. It is possible that diverse genetic backgrounds, different TAM dosing regimens or partial hepatic transgene silencing, as previously reported 33, 51 , could explain these differences.
Our findings highlight the RSPO-LGR4/5-ZNRF3/RNF43 module as a master regulator of Wnt/β-catenin-mediated metabolic liver zonation and as a growth/size control rheostat during liver development, homeostasis and regeneration. The growth-promoting effect of ectopic RSPO1 in livers highlights its potential use for regenerative therapies.
METHODS
Methods and any associated references are available in the online version of the paper. 
M E T H O D S
instructions. Labelled probe oligonucleotides, conjugated to alkaline phosphatase type 1 (LP-AP type 1) and type 6 (LP-AP type 6), were added, and fast red and fast blue substrates were used to detect the target genes. Slides were counterstained with Meyer's haematoxylin and embedded with a DAPI-containing aqueous mounting medium (Roti-Mount FluorCare DAPI, Roth AG).
Fluorescence ISH of Axin2 and Znrf3 was performed using the RNAscope Assay Kit (ACD Europe SRL) according to the manufacturer's instructions. Briefly, 10 µm fresh-frozen liver cryosections were fixed with 10% neutral-buffered formalin for 15 min at 4 • C, washed, dehydrated and air-dried. Sections were pre-treated with pretreatment solution for fluorescence (ACD, 320842) for 30 min at room temperature, and hybridized for 2 h at 40 • C with MmAxin2 (probe 400331) and custommade MmZnrf3 probes. Sections were subsequently pre-amplified and amplified according to the manufacturer's instructions. Slides were counterstained with DAPI and mounted.
ISH images were acquired using a laser scanning confocal microscope (LSM710, Carl Zeiss Microscopy GmbH), using Zen software and fixed parameters. Signal intensity was adjusted on each channel according to their histograms and using fixed parameters across the whole batch of pictures. Images were quantified using ImageJ. ISH of Lgr4 and Lgr5 was repeated 3 times, ISH of Axin2 was repeated 2 times and ISH of Znrf3 was carried out once, each on 5 mice.
Protein production and purification. A recombinant RSPO1-Fc fusion was generated by fusing the R-spondin-1 (amino acids 31-210) sequence to the Fc domain of IgG1 and placed into a mammalian expression vector. The DNA construct was transfected into HEK 293F cells (Invitrogen) using a 1:3 ratio of DNA/PEI. The cells were placed at 37 • C, 8% CO 2 in shaker flasks and incubated for 6 days. Purification was performed by Protein A chromatography (GE) followed by a size exclusion chromatography polishing step in PBS. The integrity of the protein was assessed by SDS-PAGE and LCMS and determined to be greater than 90% pure. WT, control and Lgr4/5dLKO mice 11-14 weeks of age and Tcf/Lef-Venus mice 8 weeks of age were injected i.v. with 10 mg kg −1 RSPO1 for the times indicated in each figure.
RNA extraction, reverse transcription and quantitative RT-PCR (qPCR).
Total liver RNA was isolated using the RNeasy mini kit including on-column DNase digestion according to the manufacturer's instructions (Qiagen). RNA quality was assessed with the RNA 6000 Nano Kit (Agilent). Two micrograms of RNA from each tissue sample was reverse-transcribed using the high-capacity cDNA reverse transcription kit (Applied Biosystems). The resulting cDNA products were diluted 1:20 and subjected to qPCR reactions using TaqMan reagents (Supplementary  Table 3 , Applied Biosystems). Specifically, qPCR reactions were conducted by initial incubation at 50 • C for 2 min, 95 • C for 10 min, followed by 40 cycles of 95 • C for 15 s and 60 • C for 1 min, each. Experiments were run on an ABI Prism 7900HT Sequence Detection System (Applied Biosystems) and data processing was performed using the SDS v2.4 and RQ manager v1.2 software. The threshold crossing value (Ct) was determined for each transcript and normalized to the internal control transcript (β-actin or Gapdh). The relative quantification of each mRNA species was assessed using the comparative Ct method (Livak, Ct). Shown are average fold changes of each transcript normalized to control, including the respective standard deviations. Statistical analysis was performed using the Mann-Whitney test or Student's t-test with the Graphpad Prism software (Graphpad Software). P values are given in the figure legends.
RNA sequencing. RNA-sequencing libraries were prepared from mouse liver total RNA using the Illumina TruSeq Stranded Total RNA sample preparation protocol following the manufacturer's instructions. Both cytoplasmic and mitochondrial rRNA were removed with the Ribo-Zero Gold Kit. Each library was sequenced in paired-end mode, 2 × 76 bp, using the HiSeq2500 platform. A total number of 1,83 billion 76-base-pair (bp) paired-end reads was mapped to the mouse genome (GRCm38.p2 assembly) and the mouse gene transcripts from Ensembl REF1 (v76) by using an in-house gene and exon quantification pipeline based on the aligner Bowtie REF2 , version 2.0.2. On average, >70% of the total reads were mapped to the genome or the transcripts. These alignments were used to derive gene counts based on mouse Ensembl gene IDs (v76). Gene counts, which represent the total number of reads aligned to each gene, were then transformed into counts per million (CPM; normalization by total number of mapped reads per sample) and fragments per kilobase of exon per million of fragments mapped (FPKM; further normalization by effective gene length). Normalized expression mRNA values in FPKM are available in Supplementary Table 1 .
After assessment by principal component analysis and multidimensional scaling, all samples were retained for further analysis, and genes not present with at least 1 CPM in at least half the samples of a group were excluded (reduction of genes from 41,529 to 13,881). Differential gene expression was calculated using edgeR and limma/voom in R. In brief, samples were scaled to the same library size using a weighted trimmed mean of the M-values, weights for linear modelling were estimated using voom() from the limma package, linear models were fitted with lmFit() and an empirical Bayes eBayes() moderation was used to determine statistics for differentially expressed genes of each group comparison (that is, contrast), using the Benjamini-Hochberg correction for multiple hypothesis testing. Genes with a twofold change and a P value equal to or smaller than 0.01 were considered differentially expressed (see Supplementary Table 1 ). Gene set enrichment analyses were performed using Python and R scripts that conduct a series of (non-)parametric tests for each contrast 56, 57 . We performed all of the analyses using two gene rankings, where the first one is by fold change alone, and the second by the fold change multiplied by the negative logarithm of the P value; the latter version puts more weight on genes that move less, but significantly. Within a contrast, results were adjusted using the Benjamini-Hochberg method. We considered gene sets differentially expressed if they had both a weighted Kolmogorov-Smirnov statistic equal to or greater than 0.5 and a Mann-Whitney U test P value equal to or smaller than 0.001. All pathways that were within the top 50 by either ranking were manually inspected (see Supplementary Table 2 Statistical analysis. Data are presented as mean ± standard deviation (s.d.). n refers to biological replicates. P < 0.05 was considered statistically significant. Prism software (GraphPad software) was used for statistical analyses. No statistical method was used to predetermine sample size. No samples or animals were excluded from the analysis. The experiments were not randomized. For MRI analysis, the investigators were blinded by a third party. Unblinding was performed immediately before final data analysis. Data are expected to have normal distribution. Data significance was analysed using a two-tailed, unpaired Student's t-test in cases where two groups were being compared. In cases where more than two groups were being compared, one-or two-way ANOVA was used. Tukey's or Sidak's tests were used to correct for multiple comparisons. 
